Next Article in Journal
PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP
Previous Article in Journal
Plant-Derived Nano and Microvesicles for Human Health and Therapeutic Potential in Nanomedicine
Article

UVA-Degradable Collagenase Nanocapsules as a Potential Treatment for Fibrotic Diseases

1
Departamento de Química en Ciencias Farmacéuticas, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria, Hospital 12 de Octubre i+12, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain
2
CIBER de Bioingeniería, Biomateriales y Nanomedicina, CIBER-BBN, 28029 Madrid, Spain
3
Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Universidad Complutense de Madrid, Avenida Córdoba s/n, 28041 Madrid, Spain
4
Departamento de Materiales y Producción Aeroespacial, ETSI Aeronáutica y del Espacio, Universidad Politécnica de Madrid, 28040 Madrid, Spain
5
Servicio de Dermatología, Hospital 12 de Octubre, Instituto (i+12 Medical School), Universidad Complutense de Madrid, Avenida Córdoba s/n, 28041 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Academic Editors: Dimitris Tsiourvas and Luisa Di Marzio
Pharmaceutics 2021, 13(4), 499; https://doi.org/10.3390/pharmaceutics13040499
Received: 8 March 2021 / Revised: 30 March 2021 / Accepted: 2 April 2021 / Published: 6 April 2021
Peyronie and Dupuytren are pathologies characterized by the appearance of localized fibrotic lesions in an organ. These disorders originate from an excessive production of collagen in the tissue provoking dysfunction and functional limitations to the patients. Local administration of collagenase is the most used treatment for these fibrotic-type diseases, but a high lability of the enzyme limits its therapeutic efficacy. Herein, we present a novel methodology for the preparation of collagenase nanocapsules without affecting its enzymatic activity and capable of releasing the enzyme in response to an ultraviolet A (UVA) light stimulus. Polymeric coating around collagenase was formed by free-radical polymerization of acrylamide-type monomers. Their degradation capacity under UVA irradiation was provided by incorporating a novel photocleavable acrylamide-type crosslinker within the polymeric framework. This property allowed collagenase release to be triggered in a controlled manner by employing an easily focused stimulus. Additionally, UVA irradiation presents considerable benefits by itself due to its capacity to induce collagenase production in situ. An expected synergistic effect of collagenase nanocapsules in conjunction with UVA effect may present a promising treatment for these fibrotic diseases. View Full-Text
Keywords: photolinker; collagenase nanocapsules; fibrotic diseases; collagen; UVA photolinker; collagenase nanocapsules; fibrotic diseases; collagen; UVA
Show Figures

Graphical abstract

MDPI and ACS Style

Moreno, V.M.; Meroño, C.; Baeza, A.; Usategui, A.; Ortiz-Romero, P.L.; Pablos, J.L.; Vallet-Regí, M. UVA-Degradable Collagenase Nanocapsules as a Potential Treatment for Fibrotic Diseases. Pharmaceutics 2021, 13, 499. https://doi.org/10.3390/pharmaceutics13040499

AMA Style

Moreno VM, Meroño C, Baeza A, Usategui A, Ortiz-Romero PL, Pablos JL, Vallet-Regí M. UVA-Degradable Collagenase Nanocapsules as a Potential Treatment for Fibrotic Diseases. Pharmaceutics. 2021; 13(4):499. https://doi.org/10.3390/pharmaceutics13040499

Chicago/Turabian Style

Moreno, Víctor M., Carolina Meroño, Alejandro Baeza, Alicia Usategui, Pablo L. Ortiz-Romero, José L. Pablos, and María Vallet-Regí. 2021. "UVA-Degradable Collagenase Nanocapsules as a Potential Treatment for Fibrotic Diseases" Pharmaceutics 13, no. 4: 499. https://doi.org/10.3390/pharmaceutics13040499

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop